TOP-PIC: a new tool to optimize pharmacotherapy and reduce polypharmacy in patients with incurable cancer

J Cancer Res Clin Oncol. 2023 Aug;149(10):7113-7123. doi: 10.1007/s00432-023-04671-9. Epub 2023 Mar 6.

Abstract

Purpose: Polypharmacy is a significant problem in patients with incurable cancer and a method to optimize pharmacotherapy in this patient group is lacking. Therefore, a drug optimization tool was developed and tested in a pilot test.

Methods: A multidisciplinary team of health professionals developed a "Tool to Optimize Pharmacotherapy in Patients with Incurable Cancer" (TOP-PIC) for patients with a limited life expectancy. The tool consists of five sequential steps to optimize medications, including medication history, screening for medication appropriateness and drug interactions, a benefit-risk assessment using the TOP-PIC Disease-based list, and shared decision-making with the patient. For pilot testing of the tool, 8 patient cases with polypharmacy were analyzed by 11 oncologists before and after training with the TOP-PIC tool.

Results: TOP-PIC was considered helpful by all oncologists during the pilot test. The median additional time required to administer the tool was 2 min per patient (P < 0.001). For 17.4% of all medications, different decisions were made by using TOP-PIC. Among possible treatment decisions (discontinuation, reduction, increase, replacement, or addition of a drug), discontinuation of medications was the most common. Without TOP-PIC, physicians were uncertain in 9.3% of medication changes, compared with only 4.8% after using TOP-PIC (P = 0.001). The TOP-PIC Disease-based list was considered helpful by 94.5% of oncologists.

Conclusions: TOP-PIC provides a detailed, disease-based benefit-risk assessment with recommendations specific for cancer patients with limited life expectancy. Based on the results of the pilot study, the tool seems practicable for day-to-day clinical decision-making and provides evidence-based facts to optimize pharmacotherapy.

Keywords: Cancer; Clinical decision-making; Drug therapy; Polypharmacy; Potentially inappropriate medication list; Risk assessment.

MeSH terms

  • Clinical Decision-Making
  • Health Personnel
  • Humans
  • Neoplasms* / drug therapy
  • Pilot Projects
  • Polypharmacy*
  • Potentially Inappropriate Medication List